Promising Safety and Efficacy Data of Radspherin® Unveiled
Oncoinvent AS, a clinical stage company zeroing in on advanced alpha emitter therapy for various solid cancers, has recently shared crucial findings from their Phase 1/2a study of Radspherin®. This research focuses on patients battling colorectal cancer, showcasing its potential through a peer-reviewed publication.
Insight into the Phase 1/2a Study
The publication, which aired in a respected scientific journal, reveals that the safety and efficacy data over 18 months was derived from 23 patients enrolled in the Phase 1 segment of the RAD-18-002 study. Previously, these findings captured the attention of delegates at the 2023 Peritoneal Surface Oncology Group International Congress.
Expert Endorsements
Professor Emeritus Oyvind Bruland, MD, PhD, a senior author of this publication and one of Oncoinvent’s co-founders, expressed his satisfaction with the publication, emphasizing the implications this research holds for treating peritoneal metastases in colorectal cancer patients. He highlighted that there is a significant and pressing need for novel treatments in this area.
Challenges in Treating Metastases
According to Stein G. Larsen, MD, PhD, the principal investigator of the study and chief gastrosurgeon at Oslo University Hospital, the current treatment landscape is limited. Patients with liver and lung metastases often have access to multiple new treatment options, unlike those suffering from peritoneal metastases.
Key Findings and Implications
The published data revealed that Radspherin® demonstrated excellent tolerability following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Remarkably, at the 18-month mark, none of the patients who received the recommended dose of 7?MBq exhibited peritoneal recurrences.
Future Studies on Radspherin®
Radspherin® showed early efficacy signals that warrant additional clinical evaluation. Anticipation grows as results from an additional 24 patients treated with Radspherin® in the RAD-18-002 study are forthcoming. This may provide deeper insights into the treatment's potential impact.
Understanding the RAD-18-002 Study
Designed as a Phase 1/2a open-label trial, the RAD-18-002 study primarily aims to determine the clinical dose and evaluate Radspherin®'s safety and tolerability. It specifically targets patients with peritoneal metastases scheduled for cytoreduction and HIPEC. Recruitment for this study concluded at the end of 2023.
What is Radspherin®?
Radspherin® represents an innovative investigational radiopharmaceutical tailored for the local treatment of cancer spreading to body cavities. Formulated from billions of calcium carbonate microparticles infused with radium-224, Radspherin® utilizes the decay of radium-224 to emit alpha particles, delivering a powerful form of ionizing radiation.
Clinical Applications of Radspherin®
Radspherin® is currently being investigated in clinical studies catering to peritoneal metastases stemming from ovarian and colorectal cancer. It’s administered intraperitoneally post-surgical resection, with the goal of completely removing all detectable tumors.
The Vision of Oncoinvent AS
Oncoinvent AS strives to revolutionize cancer treatment through targeted radiopharmaceuticals. Their team comprises experienced professionals dedicated to advancing the clinical development of innovative treatments, such as Radspherin®. Their investments in internal manufacturing and supply capabilities position them well to support multi-center phase 2 clinical trials effectively.
Frequently Asked Questions
What is the purpose of the RAD-18-002 study?
The RAD-18-002 study aims to evaluate the safety, tolerability, and efficacy of Radspherin® administered to colorectal cancer patients undergoing surgery.
How many patients were involved in the study?
The initial phase involved 23 patients, with results pending from 24 additional participants.
What is Radspherin® used for?
Radspherin® is designed for locally treating cancer that has spread to body cavities, particularly focusing on colorectal and ovarian cancers.
Who are the key researchers behind this study?
Professor Oyvind Bruland and Dr. Stein G. Larsen are among the leading experts contributing to this research.
How does Radspherin® work?
Radspherin® uses radium-224's radioactive decay to emit alpha particles directly targeting cancer cells, which can enhance treatment efficacy.
